oxaliplatin

PET-NPs were readily internalized by gastric cancer cells, leading to enhanced cell proliferation, migration, and resistance to Oxaliplatin, accompanied by suppression of apoptosis and immunogenic cell death...Moreover, PET-NPs profoundly remodeled the tumor immune microenvironment by promoting M2 macrophage polarization, reducing CD8+ T cell infiltration, upregulating immune checkpoint molecules TIGIT and PD-1, and suppressing key antitumor cytokines, including IFN-γ and TNF-α. Collectively, these findings demonstrate that PET-NPs act as a previously underrecognized environmental risk factor that accelerates gastric cancer progression through direct molecular interference and immune suppression, highlighting the potential public health implications of chronic microplastic exposure.

Additionally,TDG expression was positively associated with tumor mutational burden (P<0.001),microsatellite instability (P=0.045),mutant-allele tumor heterogeneity (P=0.001),and tumor neoantigens (P<0.001) in lung adenocarcinoma.In lung adenocarcinoma,the expression of TDG was notably elevated in the tumor tissue compared with that in adjacent normal tissue (P<0.001).Male patients exhibited higher levels of TDG expression than female patients (P=0.002),and smokers demonstrated higher TDG expression than non-smokers (P<0.001).Furthermore,TDG expression was correlated with smoking cessation duration (P=0.014).Positive correlations were observed for TDG expression with both clinical T stage (P=0.003) and distant metastasis (P=0.012),while a negative correlation was found with patient prognosis (P=0.030).Furthermore,TDG emerged as an independent prognostic factor for lung adenocarcinoma.In vitro experiments revealed that silencing TDG inhibited the proliferation and migration of lung adenocarcinoma cells (both P<0.05).A correlation analysis between TDG-related genes and target kinases revealed that in lung adenocarcinoma,genes encoding aurora kinase A,cyclin-dependent kinase 2 and other enzymes exhibited positive correlations with TDG expression (all P<0.001).Furthermore,TDG expression demonstrated positive correlations with functional states including the cell cycle,DNA damage,and DNA repair processes (all P<0.001).In addition,the expression of TDG was correlated with the efficacy of treatment in the first course in clinical patients (P=0.007).Specifically,TDG expression levels were higher in the progressive disease group than in the stable disease group (P=0.016),and lower in the complete remission group than in the progressive disease group (P<0.001).Additionally,elevated TDG expression was associated with enhanced resistance to oxaliplatin (P<0.001),carmustine (P<0.001),and olaparib (P=0.004). Conclusion TDG serves as a potential prognostic biomarker,an immunotherapeutic target,and a oncogene in pan-cancer,with particular significance in lung adenocarcinoma.

5-FU cardiotoxicity may present late and exhibit multifaceted manifestations and requires a multidisciplinary approach to balance oncologic efficacy with cardiovascular safety.

P3, N=378, Active, not recruiting, Erasmus Medical Center | Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2026 --> Jan 2027

P2, N=170, Recruiting, Mirati Therapeutics Inc. | Not yet recruiting --> Recruiting

P3, N=190, Active, not recruiting, Taizhou Hanzhong biomedical co. LTD | Recruiting --> Active, not recruiting

P2, N=90, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital

P3, N=703, Active, not recruiting, Merck Sharp & Dohme LLC | Trial completion date: Feb 2027 --> Jun 2026 | Trial primary completion date: Feb 2027 --> Jan 2026

P1/2, N=138, Recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University | Not yet recruiting --> Recruiting | Initiation date: Jan 2026 --> Apr 2026

P3, N=874, Recruiting, Shanghai Shengdi Pharmaceutical Co., Ltd | Not yet recruiting --> Recruiting

P3, N=600, Not yet recruiting, NingBo Junyan Hongshi Biosciences Co., Ltd

P3, N=450, Active, not recruiting, University of Birmingham | Trial completion date: Aug 2027 --> Dec 2027 | Trial primary completion date: Aug 2026 --> Dec 2026